Halozyme Therapeutics Reports 22% Revenue Growth to $354.3 Million in Latest Quarter

Halozyme Therapeutics, Inc. reported significant financial performance in its latest quarterly filing, with total revenues reaching $354.3 million for the three months ended September 30, 2025, a 22% increase from $290.1 million in the same period last year. The growth was primarily driven by a 52% rise in royalties, which amounted to $236.0 million, largely attributed to the strong sales of ENHANZE partner products, including VYVGART Hytrulo and DARZALEX SC. Product sales also saw a modest increase, totaling $94.2 million, up from $86.7 million, while revenues under collaborative agreements decreased by 50% to $24.0 million, reflecting the timing of milestone achievements.

In terms of profitability, Halozyme reported a net income of $175.2 million for the third quarter, compared to $137.0 million in the prior year, resulting in diluted earnings per share of $1.43, up from $1.05. For the nine months ended September 30, 2025, net income was $458.5 million, significantly higher than $307.1 million for the same period in 2024. The company’s operating income also increased to $217.9 million, up from $163.2 million year-over-year, reflecting effective cost management despite rising operating expenses.

The company has made strategic moves, including the planned acquisition of Elektrofi, Inc. for $750 million, which is expected to enhance its capabilities in biologics delivery technology. This acquisition is anticipated to close in the fourth quarter of 2025, pending regulatory review. Additionally, Halozyme has continued its share repurchase program, utilizing $92.3 million to buy back approximately 1.7 million shares at an average price of $52.89 per share as part of a broader $750 million repurchase authorization initiated in February 2024.

Operationally, Halozyme has seen an increase in its cash and cash equivalents, which rose to $419.7 million as of September 30, 2025, compared to $115.9 million at the end of 2024. The company’s total assets increased to $2.2 billion, driven by higher accounts receivable and inventory levels. The company’s employee headcount remained stable, supporting its ongoing research and development efforts, which totaled $17.3 million for the quarter, slightly down from $18.5 million in the previous year.

Looking ahead, Halozyme anticipates continued growth in royalty revenues driven by the increasing uptake of ENHANZE partner products and the launch of new products. The company expects to maintain its strong financial position, supported by its existing cash reserves and anticipated revenues from collaborative agreements. However, it also acknowledges potential fluctuations in revenues under collaborative agreements based on the timing of milestone achievements and market conditions.